NCT07795268
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Aug 31, 2026 to Nov 13, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Overall Survival (OS)
Timeframe: From date of randomization until date of death from any cause, assessed up to 36months (estimated final OS analysis)
Secondary (13)
Radiographic progression-free survival (rPFS)
Number of participants with Treatment Emergent Adverse Events
Overall Response Rate (ORR)
Disease control rate (DCR)
Duration of Response (DOR)
Show 8 moreShow less
Time to first Symptomatic Skeletal Event (SSE)
Progression-free survival (PFS)
Biochemical response
Prostate-specific antigen 80 (PSA80) response
Duration of PSA response
European Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)
Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire
Brief Pain Inventory-short Form (BPI-SF)
Arms and interventions
177Lu-NYM032 plus BSC/BSoCExperimental
Patients randomized to receive the investigational product will receive 7.4 GBq (+/- 10%) 177Lu-NYM032 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BSC/BSoC) may be used.
BSC/BSoC aloneOther
Patients randomized to this arm will receive best supportive/best standard of care (BSC/BSoC) as determined by the investigator.
Drugs: 177Lu-NYM032 injection
Other: Best supportive/best standard of care
Sites
1 site in 1 country
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China